Download PDF
Fortschr Neurol Psychiatr 2010; 78(5): 279-287
DOI: 10.1055/s-0029-1245307
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Therapie psychischer Störungen bei Morbus Parkinson

Treatment of Mental Disorders in Patients with Parkinson’s DiseaseU. Meincke1, 2 , C. M. Kosinski3
  • 1Klinik für Psychiatrie und Psychotherapie Klinikum Niederberg, Lehrkrankenhaus der Universität Duisburg-Essen
  • 2Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum der RWTH Aachen
  • 3Klinik für Neurologie, Medizinisches Zentrum Kreis Aachen gGmbH, Lehrkrankenhaus der RWTH Aachen
Further Information

Publication History

Publication Date:
26 April 2010 (online)

    Permissions and Reprints

Zusammenfassung

Patienten mit Morbus Parkinson haben ein hohes Risiko für die Entwicklung psychischer Störungen, wie insbesondere depressive oder psychotische Syndrome, Demenz oder Schlafstörungen. Obwohl diese psychischen Erkrankungen häufig dem Beginn der motorischen Symptomatik vorausgehen, bleiben sie nicht selten unerkannt und somit unbehandelt. Die vorliegende Arbeit gibt einen umfassenden Überblick über therapeutische Optionen psychopathologischer Syndrome bei Morbus Parkinson. Bei depressiven Syndromen ist die dopaminerge Medikation zu optimieren, insbesondere durch Gabe von Dopamin-Agonisten. In aktuellen Studien zeigten trizyklische Antidepressiva stärkere antidepressive Effekte als SSRI. Psychotische Symptome treten meist unter Gabe von dopaminergen Substanzen auf oder im Rahmen eines demenziellen Abbaus. Bei der Einstellung sollte L-Dopa in möglichst niedriger Dosis eingesetzt werden, gegebenenfalls in Kombination mit COMT-Inhibitoren. Falls eine antipsychotische Therapie angezeigt ist, ist Clozapin Mittel der ersten Wahl. Aber auch die Gabe von Quetiapin kann hilfreich sein. Psychotische Symptome bei dementen Patienten sprechen häufig auf Cholinesterasehemmer an, die gleichzeitig den kognitiven Abbau verzögern können. Patienten mit Morbus Parkinson benötigen eine individuell ausgerichtete Therapie nicht nur für die motorische Symptomatik, sondern auch für die häufig auftretenden psychischen Syndrome. Diese beeinflussen maßgeblich die Lebensqualität des Patienten und seiner Angehörigen, sind prädiktiv für Hospitalisation und haben daher eine große ökonomische Bedeutung für Gesundheitssysteme.

Abstract

Patients with Parkinson’s disease (PD) have a high risk of psychiatric complications, like depressive or psychotic syndromes, dementia and sleep disorders. Although these disorders may even precede the onset of motor symptoms, they are often not recognized and therefore not adequately treated. This article provides a comprehensive overview of the therapeutic options of the most commonly observed psychopathological syndromes in PD. In the case of depressive syndromes medication could be optimized by making use of dopamine agonists that have been proven to have antidepressant properties. In recent studies tricyclic antidepressants showed stronger effects than SSRI. Psychotic symptoms are most often evoked by dopaminergic therapy or are seen in the course of cognitive decline. The therapeutic regimen should be built mainly on L-Dopa medication in the lowest tolerated dose, if required in combinations with COMT-Inhibitors. When antipsychotic medication is indicated, clozapine is the first choice. Quetiapine might also be useful in many patients. Psychotic symptoms in demented patients may respond to Cholinesterase-Inhibitors, that also delay cognitive decline. Patients with PD require an individually optimized therapeutic regimen not only for motor symptoms, but also for frequently occurring psychiatric syndromes since these strongly influence the patients’ and their caregivers’ quality of life, are predictors for hospitalization and therefore have great economic importance for health care systems.

Schlüsselwörter

Demenz - Depression - Morbus Parkinson - Psychose

Keywords

dementia - depression - Parkinson’s disease - psychosis

Literatur

  • 1 Aarsland D, Larsen J P, Tandberg E et al. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study.  J Am Geriatr Soc. 2000;  48 (8) 938-942
    Google Scholar
  • 2 Global Parkinson’s Disease Survey Steering Committee . Factors impacting on quality of life in Parkinson’s disease: results from an international survey.  Mov Disord. 2002;  17 (1) 60-67
    Google Scholar
  • 3 Bohnen N I, Kaufer D I, Ivanco L S et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.  Arch Neurol. 2003;  60 (12) 1745-1748
    Google Scholar
  • 4 Doder M, Rabiner E A, Turjanski N et al. Tremor in Parkinson’s disease and serotonergic dysfunction: an 11C-WAY 100 635 PET study.  Neurology. 2003;  60 601-605
    Google Scholar
  • 5 Remy P, Doder M, Lees A et al. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system.  Brain. 2005;  128 1314-1322
    Google Scholar
  • 6 Menza M A, Mark M H. Parkinson’s disease and depression: the relationship to disability and personality.  J Neuropsychiatry Clin Neurosci. 1994;  6 (2) 165-169
    Google Scholar
  • 7 Schuurman A G, Akker van den M, Ensinck K T et al. Increased risk of Parkinson’s disease after depression: a retrospective cohort study.  Neurology. 2002;  58 (10) 1501-1543
    Google Scholar
  • 8 Leentjens A F, Van den Akker M, Metsemakers J F et al. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study.  Mov Disord. 2003;  18 (4) 414-418
    Google Scholar
  • 9 Starkstein S E, Petracca G, Chemerinski E et al. Depression in classic versus akinetic-rigid Parkinson’s disease.  Mov Disord. 1998;  13 (1) 29-33
    Google Scholar
  • 10 Mayberg H S, Starkstein S E, Sadzot B et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease.  Ann Neurol. 1990;  28 (1) 57-64
    Google Scholar
  • 11 Ring H A, Bench C J, Trimble M R et al. Depression in Parkinson’s disease. A positron emission study.  Br J Psychiatry. 1994;  165 (3) 333-339
    Google Scholar
  • 12 Mallet L, Schüpbach M, N’Diaye K et al. Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behaviour.  Proc Natl Acad Sci USA. 2007;  104 10661-10666
    Google Scholar
  • 13 Reijnders J S, Ehrt U, Weber W E et al. A systematic review of prevalence studies of depression in Parkinson’s disease.  Mov Disord. 2008;  23 (2) 183-189
    Google Scholar
  • 14 Storch A, Ebersbach G, Fuchs G et al. Depression beim idiopathischen Parkinson-Syndrom. Epidemiologie, Pathophysiologie, Klinik und Diagnostik.  Fortschr Neurol Psychiatr. 2008;  76 715-724
    Google Scholar
  • 15 Nazem S, Siderow A D, Duda J E et al. Suicidal and death ideation in Parkinson’s disease.  Mov Disord. 2008;  23 (11) 1573-1579
    Google Scholar
  • 16 Papapetropoulos S, Ellul J, Argyriou A A et al. The effect of depression on motor function and disease severity of Parkinson’s disease.  Clin Neurol Neurosurg. 2006;  108 (5) 465-469
    Google Scholar
  • 17 Maricle R A, Nutt J G, Valentine R J et al. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson’s disease: a double-blind, placebo-controlled study.  Neurology. 1995;  45 1757-1760
    Google Scholar
  • 18 Fetoni V, Soliveri P, Monza D et al. Affective symptoms in multiple system atrophy and Parkinson’s disease: response to levodopa therapy.  J Neurol Neurosurg Psychiatry. 1999;  66 541-544
    Google Scholar
  • 19 Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study.  J Neurol. 2006;  253 (5) 601-607
    Google Scholar
  • 20 Rektorová I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study.  Eur J Neurol. 2003;  10 (4) 399-406
    Google Scholar
  • 21 Reichmann H, Brecht M H, Köster J et al. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson’s disease.  CNS Drugs. 2003;  17 (13) 965-973
    Google Scholar
  • 22 Lemke M R, Brecht H M, Koester J et al. Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexole.  J Neuropsychiatry Clin Neurosci. 2005;  17 (2) 214-220
    Google Scholar
  • 23 Leentjens A F, Koester J, Fruh B et al. The effect of pramipexole on mood and motivational symptoms in Parkinson’s disease: a meta-analysis of placebo-controlled studies.  Clin Ther. 2009;  31 (1) 89-98
    Google Scholar
  • 24 Pahwa R, Stacy M A, Factor S A et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.  Neurology. 2007;  68 (14) 1108-1115
    Google Scholar
  • 25 Buchwald B, Angersbach D, Jost W H. Die Verbesserung motorischer und nicht-motorischer Symptome bei Parkinson-Patienten unter einer Therapie mit Ropinirol.  Fortschr Neurol Psychiatr. 2007;  75 (4) 236-241
    Google Scholar
  • 26 Corrigan M H, Denahan A Q, Wright C E et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.  Depress Anxiety. 2000;  11 (2) 58-65
    Google Scholar
  • 27 Szegedi A, Wetzel H, Angersbach D et al. Response to treatment in minor and major depression: results of a double-blind comparative study with paroxetine and maprotiline.  J Affect Disord. 1997;  45 (3) 167-178
    Google Scholar
  • 28 Hauser R A, Zesiewicz T A. Sertraline for the treatment of depression in Parkinson’s disease.  Mov Disord. 1997;  12 (5) 756-759
    Google Scholar
  • 29 Ceravolo R, Nuti A, Piccinni A et al. Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms.  Neurology. 2000;  55 1216-1218
    Google Scholar
  • 30 Tesei S, Antonini A, Canesi M et al. Tolerability of paroxetine in Parkinson’s disease: a prospective study.  Mov Disord. 2000;  15 (5) 986-989
    Google Scholar
  • 31 Weintraub D, Taraborelli D, Morales K H et al. Escitalopram for major depression in Parkinson’s disease: an open-label, flexible-dosage study.  J Neuropsychiatry Clin Neurosci. 2006;  18 (3) 377-383
    Google Scholar
  • 32 Andersen J, Aabro E, Gulmann N et al. Anti-depressive treatment in Parkinson’s disease. A controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-DOPA.  Acta Neurol Scand. 1980;  62 (4) 210-219
    Google Scholar
  • 33 Laitinen L. Desipramine in treatment of Parkinson’s disease. A placebo-controlled study.  Acta Neurol Scand. 1969;  45 (1) 109-113
    Google Scholar
  • 34 Menza M, Dobkin R D, Marin H et al. A controlled trial of antidepressants in patients with Parkinson disease and depression.  Neurology. 2009;  72 (10) 886-892
    Google Scholar
  • 35 Devos D, Dujardin K, Poirot I et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study.  Mov Disord. 2008;  23 (6) 850-857
    Google Scholar
  • 36 Steur E N, Ballering L A. Moclobemide and selegeline in the treatment of depression in Parkinson’s disease.  J Neurol Neurosurg Psychiatry. 1997;  63 (4) 547
    Google Scholar
  • 37 Pintor L, Baillès E, Valldeoriola F et al. Response to 4-month treatment with reboxetine in Parkinson’s disease patients with a major depressive episode.  Gen Hosp Psychiatry. 2006;  28 (1) 59-64
    Google Scholar
  • 38 Lemke M R. Effect of reboxetine on depression in Parkinson’s disease patients.  J Clin Psychiatry. 2002;  63 (4) 300-304
    Google Scholar
  • 39 Fregni F, Simon D K, Wu A et al. Non-invasive brain stimulation for Parkinson’s disease: a systematic review and meta-analysis of the literature.  J Neurol Neurosurg Psychiatry. 2005;  76 (12) 1614-1623
    Google Scholar
  • 40 Epstein C M, Evatt M L, Funk A et al. An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson’s disease.  Clin Neurophysiol. 2007;  118 (10) 2189-2194
    Google Scholar
  • 41 Papapetropoulos S, Mash D C. Psychotic symptoms in Parkinson’s disease. From description to etiology.  J Neurol. 2005;  252 (7) 753-764
    Google Scholar
  • 42 Fénelon G, Mahieux F, Huon R et al. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors.  Brain. 2000;  123 733-745
    Google Scholar
  • 43 Ebersbach G. Halluzinationen und Psychose bei der Parkinson-Erkrankung.  Nervenheilkunde. 2008;  27 709-716
    Google Scholar
  • 44 Goetz C G, Stebbins G T. Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease.  Neurology. 1995;  45 (4) 669-671
    Google Scholar
  • 45 Schwab R S, Fabing H D, Prichard J S. Psychiatric symptoms and syndromes in Parkinson’s disease.  Am J Psychiatry. 1950;  107 901-907
    Google Scholar
  • 46 Winter C, Juckel G, Plotkin M et al. Paranoid schizophrenia and idiopathic Parkinson’s disease do coexist: a challenge for clinicians.  Psychiatry Clin Neurosci. 2006;  60 (5) 639
    Google Scholar
  • 47 Wolters E C. Intrinsic and extrinsic psychosis in Parkinson’s disease.  J Neurol. 2001;  248 III22-III27 (S 03)
    Google Scholar
  • 48 Poewe W. Psychosis in Parkinson’s disease.  Mov Disord. 2003;  18 S80-S87 (S 06)
    Google Scholar
  • 49 Saint-Cyr J A, Taylor A E, Lang A E. Neuropsychological and psychiatric side effects in the treatment of Parkinson’s disease.  Neurology. 1993;  43 (12) S47-S52 (S 06)
    Google Scholar
  • 50 Parkinson Study Group . Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.  JAMA. 2000;  284 (15) 1931-1938
    Google Scholar
  • 51 Oertel W H. Pergolide versus L-dopa.  Mov Disord. 2000;  15 S4
    Google Scholar
  • 52 Rascol O, Montastruc J L. Role of dopaminergic agonists.  Rev Neurol. 2000;  156 98-104 (S NNN)
    Google Scholar
  • 53 Rinne U K, Bracco F, Chouza C et al. Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.  Drugs. 1998;  55 23-30 (S 01)
    Google Scholar
  • 54 Korczyn A D, Brooks D J, Brunt E R et al. Ropinirole versus bromocriptine in the treatment of early Parkinson’s disease: a 6-month interim report of a 3-year study.  Mov Disord. 1998;  13 (1) 46-51
    Google Scholar
  • 55 Korczyn A D, Brunt E R, Larsen J P et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease.  Neurology. 1999;  53 (2) 364-370
    Google Scholar
  • 56 Smet de Y, Ruberg M, Serdaru M et al. Confusion, dementia and anticholinergics in Parkinson’s disease.  J Neurol Neurosurg Psychiatry. 1982;  45 (12) 1161-1164
    Google Scholar
  • 57 Poewe W H, Deuschl G, Gordin A et al. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).  Acta Neurol Scand. 2002;  105 (4) 245-255
    Google Scholar
  • 58 Parkinson Study Group . Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients.  Ann Neurol. 1997;  42 (5) 747-755
    Google Scholar
  • 59 Onofrj M, Thomas A, Iacono D et al. Switch-over from tolcapone to entacapone in severe Parkinson’s disease patients.  Eur Neurol. 2001;  46 (1) 11-16
    Google Scholar
  • 60 Rinne U K, Larsen J P, Siden A et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.  Neurology. 1998;  51 (5) 1309-1314
    Google Scholar
  • 61 Goetz C G, Pappert E J, Blasucci L M et al. Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations.  Neurology. 1998;  50 (2) 515-517
    Google Scholar
  • 62 Pacchetti C, Manni R, Zangaglia R et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease.  Mov Disord. 2005;  20 (11) 1439-1448
    Google Scholar
  • 63 Sanchez-Ramos J R, Ortoll R, Paulson G W. Visual hallucinations associated with Parkinson disease.  Arch Neurol. 1996;  53 (12) 1265-1268
    Google Scholar
  • 64 Giladi N, Treves T A, Paleacu D et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson’s disease.  J Neural Transm. 2000;  107 (1) 59-71
    Google Scholar
  • 65 Piggott M A, Marshall E F, Thomas N et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution.  Brain. 1999;  122 1449-1468
    Google Scholar
  • 66 Rinne J O, Rinne J K, Laakso K et al. Dopamine D-1 receptors in the parkinsonian brain.  Brain Res. 1985;  359 (1 – 2) 306-310
    Google Scholar
  • 67 Diener H C. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme; 2005
    Google Scholar
  • 68 The French Clozapine Parkinson Study Group . Clozapine in drug-induced psychosis in Parkinson’s disease.  Lancet. 1999;  353 2041-2042
    Google Scholar
  • 69 The Parkinson Study Group . Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease.  N Engl J Med. 1999;  340 (10) 757-763
    Google Scholar
  • 70 Pollak P, Tison F, Rascol O et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up.  J Neurol Neurosurg Psychiatry. 2004;  75 (5) 689-695
    Google Scholar
  • 71 Ondo W G, Tintner R, Voung K D et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease.  Mov Disord. 2005;  20 (8) 958-963
    Google Scholar
  • 72 Kurlan R, Cummings J, Raman R et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.  Neurology. 2007;  68 (17) 1356-1363
    Google Scholar
  • 73 Rabey J M, Prokhorov T, Miniovitz A et al. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration.  Mov Disord. 2007;  22 (3) 313-318
    Google Scholar
  • 74 Meco G, Alessandria A, Bonifati V et al. Risperidone for hallucinations in levodopa-treated Parkinson’s disease patients.  Lancet. 1994;  343 (8909) 1370-1371
    Google Scholar
  • 75 Workman R H, Orengo C A, Bakey A A et al. The use of risperidone for psychosis and agitation in demented patients with Parkinson’s disease.  J Neuropsychiatry Clin Neurosci. 1997;  9 (4) 594-597
    Google Scholar
  • 76 Leopold N A. Risperidone treatment of drug-related psychosis in patients with parkinsonism.  Mov Disord. 2000;  15 (2) 301-304
    Google Scholar
  • 77 Ford Jr B, Lynch T, Greene P. Risperidone in Parkinson’s disease.  Lancet. 1994;  344 (8923) 681
    Google Scholar
  • 78 Breier A, Sutton V K, Feldman P D et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease.  Biol Psychiatry. 2002;  52 (5) 438-445
    Google Scholar
  • 79 Ondo W G, Levy J K, Vuong K D et al. Olanzapine treatment for dopaminergic-induced hallucinations.  Mov Disord. 2002;  17 (5) 1031-1035
    Google Scholar
  • 80 Goetz C G, Blasucci L M, Leurgans S et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.  Neurology. 2000;  55 (6) 789-794
    Google Scholar
  • 81 Friedman J H, Berman R M, Goetz C G et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease.  Mov Disord. 2006;  21 (12) 2078-2081
    Google Scholar
  • 82 Friedman J H, Factor S A. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease.  Mov Disord. 2000;  15 (2) 201-211
    Google Scholar
  • 83 Juncos J L, Roberts V J, Evatt M L et al. Quetiapine improves psychotic symptoms and cognition in Parkinson’s disease.  Mov Disord. 2004;  19 (1) 29-35
    Google Scholar
  • 84 Klein C, Prokhorov T, Miniovich A et al. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis.  Clin Neuropharmacol. 2006;  29 (4) 215-219
    Google Scholar
  • 85 Morgante L, Epifanio A, Spina E et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis.  Clin Neuropharmacol. 2004;  27 (4) 153-156
    Google Scholar
  • 86 Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease.  N Engl J Med. 2004;  351 (24) 2509-2518
    Google Scholar
  • 87 Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series.  Curr Med Res Opin. 2002;  18 (5) 258-264
    Google Scholar
  • 88 Burn D, Emre M, McKeith I et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease.  Mov Disord. 2006;  21 (11) 1899-1890
    Google Scholar
  • 89 Fernandez H H, Trieschmann M E, Okun M S. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson’s disease.  Mov Disord. 2005;  20 (1) 104-105
    Google Scholar
  • 90 Emre M. Dementia associated with Parkinson’s disease.  Lancet Neurol. 2003;  2 (4) 229-237
    Google Scholar
  • 91 Aarsland D, Tandberg E, Larsen J P et al. Frequency of dementia in Parkinson disease.  Arch Neurol. 1996;  53 (6) 538-542
    Google Scholar
  • 92 McKeith I, Mintzer J, Aarsland D et al. Dementia with Lewy bodies. International Psychogeriatric Association Expert Meeting on DLB.  Lancet Neurol. 2004;  3 (1) 19-28
    Google Scholar
  • 93 Williams-Gray C H, Foltynie T, Lewis S J et al. Cognitive deficits and psychosis in Parkinson’s disease: a review of pathophysiology and therapeutic options.  CNS Drugs. 2006;  20 (6) 477-505
    Google Scholar
  • 94 Poewe W, Wolters E, Emre M et al. Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study.  Mov Disord. 2006;  21 256-261
    Google Scholar
  • 95 Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson’s disease dementia.  Cochrane Database Syst Rev 2006;  CD004747
    Google Scholar
  • 96 Darreh-Shori T, Jelic V. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer’s disease and Parkinson’s disease dementia.  Expert Opin Drug Saf. 2010;  9 167-176
    Google Scholar
  • 97 Parkinson J. An essay on the shaking palsy. Reprint from 1817.  Neuropsychiatry Clin Neurosci. 2002;  14 223-236
    Google Scholar
  • 98 Tandberg E, Larsen J P, Karlsen K. A community-based study of sleep disorders in patients with Parkinson’s disease.  Mov Disord. 1998;  13 (6) 895-899
    Google Scholar
  • 99 Tolosa E, Gaig C, Santamaría J et al. Diagnosis and the premotor phase of Parkinson disease.  Neurology. 2009;  72 S12-S20 (S 07)
    Google Scholar
  • 100 Rye D B, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD.  Neurology. 2002;  58 (3) 341-346
    Google Scholar
  • 101 Högl B, Rothdach A, Wetter T C et al. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson’s disease.  Neuropsychopharmacology. 2003;  28 (10) 1866-1870
    Google Scholar
  • 102 Arnulf I, Bonnet A M, Damier P et al. Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis.  Neurology. 2000;  55 (2) 281-288
    Google Scholar
  • 103 Comella C L, Tanner C M, Ristanovic R K et al. Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations.  Ann Neurol. 1993;  34 (5) 710-714
    Google Scholar
  • 104 Stacy M. Sleep disorders in Parkinson’s disease: epidemiology and management.  Drugs Aging. 2002;  19 (10) 733-739
    Google Scholar
  • 105 Fantini M L, Gagnon J F, Filipini D et al. The effects of pramipexole in REM sleep behavior disorder.  Neurology. 2003;  61 (10) 1418-1420
    Google Scholar
  • 106 Hobson D E, Lang A E, Martin W R et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group.  JAMA. 2002;  287 (4) 455-463
    Google Scholar
  • 107 Moskovitz C, Moses 3 rd H, Klawans H L. Levodopa-induced psychosis: a kindling phenomenon.  Am J Psychiatry. 1978;  135 (6) 669-675
    Google Scholar
  • 108 Nausieda P A, Weiner W J, Kaplan L R et al. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis.  Clin Neuropharmacol. 1982;  5 (2) 183-194
    Google Scholar
  • 109 Chaudhuri K R, Bhattacharya K, Agapito C. The use of cabergolien in noctural parkinsonian disabilities causing sleep disruption: a parallel study with controlled-released levodopa.  Eur J Neurol. 1999;  6  11-15
    Google Scholar
  • 110 Miyasaki J M, Al Hassan K et al. Punding prevalence in Parkinson’s disease.  Mov Disord. 2007;  22 (8) 1179-1181
    Google Scholar
  • 111 Weintraub D. Dopamine and impulse control disorders in Parkinson’s disease.  Ann Neurol. 2008;  64 S93-S100 (S 02)
    Google Scholar
  • 112 Katzenschlager R. Störungen von Verhalten und Impulskontrolle beim Morbus Parkinson.  Nervenheilkunde. 2008;  27 721-727
    Google Scholar
  • 113 Silveira-Moriyama L, Evans A H, Katzenschlager R et al. Punding and dyskinesias.  Mov Disord. 2006;  21 (12) 2214-2217
    Google Scholar
  • 114 Morgan J C, Iyer S S, Sethi K D. Impulse control disorders and dopaminergic drugs.  Arch Neurol. 2006;  63 (2) 298-299
    Google Scholar
  • 115 Truong D D, Bhidayasiri R, Wolters E. Management of non-motor symptoms in advanced Parkinson disease.  J Neurol Sci. 2008;  266 (1 – 2) 216-228
    Google Scholar
  • 116 Hälbig T D, Tse W, Frisinia P G. Subthalamic deep brain stimulation and impulse control in Parkinson’s disease.  Eur J Neurol. 2009;  16 493-497
    Google Scholar
  • 117 Krack P, Batir A, Van Blercom N et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease.  N Engl J Med. 2003;  349 (20) 1925-1934
    Google Scholar
  • 118 Witt K, Daniels C, Reiff J et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study.  Lancet Neurol. 2008;  7 (7) 605-614
    Google Scholar
  • 119 Heo J H, Lee K M, Paek S H et al. The effects of bilateral subthalamic nucleus deep brain stimulation (STN DBS) on cognition in Parkinson disease.  J Neurol Sci. 2008;  273 (1 – 2) 19-24
    Google Scholar
  • 120 Schneider F, Habel U, Volkmann J et al. Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease.  Arch Gen Psychiatry. 2003;  60 (3) 296-302
    Google Scholar
  • 121 Funkiewiez A, Ardouin C, Caputo E et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease.  J Neurol Neurosurg Psychiatry. 2004;  75 (6) 834-841
    Google Scholar
  • 122 Castelli L, Perozzo P, Zibetti M et al. Chronic deep brain stimulation of the subthalamic nucleus for Parkinson’s disease: effects on cognition, mood, anxiety and personality traits.  Eur Neurol. 2006;  55 (3) 136-144
    Google Scholar
  • 123 Castelli L, Zibetti M, Rizzi L et al. Neuropsychiatric symptoms three years after subthalamic DBS in PD patients: a case-control study.  J Neurol. 2008;  255 (10) 1515-1520
    Google Scholar
  • 124 Ulla M, Thobois S, Lemaire J J et al. Manic behaviour induced by deep brain stimulation in Parkinson’s disease: evidence of substantia nigra implication?.  J Neurol Neurosurg Psychiatry. 2006;  77 1363-1366
    Google Scholar
  • 125 Drapier S, Damier P. Continuous subthalamic neurostimulation in Parkinson’s disease. Indications and modalities.  Presse Med. 2003;  32 (28) 1334-1339
    Google Scholar
  • 126 Czernecki V, Schüpbach M, Yaici S et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom.  Mov Disord. 2008;  23 (7) 964-969
    Google Scholar
  • 127 Berney A, Vingerhoets F, Perrin A et al. Effect on mood of subthalamic DBS for Parkinson’s disease: a consecutive series of 24 patients.  Neurology. 2002;  59 (9) 1427-1429
    Google Scholar
  • 128 Voon V, Krack P, Lang A E et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease.  Brain. 2008;  131 2720-2728
    Google Scholar
  • 129 Soulas T, Gurruchaga J M, Palfi S et al. Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson’s disease.  J Neurol Neurosurg Psychiatry. 2008;  79 (8) 952-954
    Google Scholar
  • 130 Hilker R, Benecke R, Deuschl G et al. Tiefe Hirnstimulation beim idiopathischen Parkinson-Syndrom: Empfehlungen der Deutschen Arbeitsgemeinschaft Tiefe Hirnstimulation.  Nervenarzt. 2009;  80 (6) 646-655
    Google Scholar
  • 131 Kalbe E, Voges J, Weber T et al. Frontal FDG-PET activity correlates with cognitive outcome after STN-DBS in Parkinson’s disease.  Neurology. 2009;  72 42-49
    Google Scholar
  • 132 Mallet L, Polosan M, Jaafari N et al. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder.  New Engl J Med. 2008;  359 2121-2134
    Google Scholar

Dr. Ulrich Meincke

Psychiatrie und Psychotherapie Klinikum Niederberg

Robert-Koch-Str. 2

42549 Velbert

Email: Meincke@Klinikum-Niederberg.de

Email:

      >